GRN-529 is a drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5).

[1] A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism.

[2] Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression.

It is theorized to work by reducing glutamate receptor hyperactivity.

[3] This drug article relating to the nervous system is a stub.